Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody
Compose a Response to This Article
Other responses
No responses have been published for this article.
